Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15534865 | 0.86 | CCR1 (0.61) | CCR1CAPN1CTSKCTSLCTSB | |
| SCHEMBL17292360 | 0.86 | CCR1 (0.61) | CCR1CAPN1CTSKCTSLCTSB | |
| SCHEMBL30959962 | 0.82 | JAK2 (0.61) | JAK2JAK1KMT2AGPR119MEN1 | |
| SCHEMBL30960033 | 0.82 | JAK2 (0.61) | JAK2JAK1KMT2AGPR119MEN1 | |
| SCHEMBL30960004 | 0.82 | JAK2 (0.61) | JAK2JAK1KMT2AGPR119MEN1 | |
| SCHEMBL19816220 | 0.82 | PREP (0.54) | CTSKCTSLCTSBMAPK1CTSS | |
| SCHEMBL19816576 | 0.82 | PREP (0.54) | CTSKCTSLCTSBMAPK1CTSS | |
| SCHEMBL19816218 | 0.82 | PREP (0.54) | CTSKCTSLCTSBMAPK1CTSS | |
| SCHEMBL26100843 | 0.80 | GPR119 (0.61) | JAK2JAK1KMT2AGPR119MEN1 | |
| SCHEMBL30965696 | 0.80 | GPR119 (0.61) | JAK2JAK1KMT2AGPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062057-B2 | CCR5 antagonists for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140221420-A1 | CCR5 ANTAGONISTS FOR TREATING HIV | PURDUE RESEARCH FOUNDATION (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221420-A1 | CCR5 ANTAGONISTS FOR TREATING HIV | CCR5, CXCR4, CXCR3 | CCR1 6/4885JAK2 2324/4885JAK1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.